Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Summarize the 2023 performance of World Ex Us dividend ETFs, highlighting key drivers, top contributors, and implications for investors.
22,394 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
MillerKnoll stock crashed today after a quarterly miss and softer guidance rattled investors. This deep dive explains...
After a sharp early-2026 retreat, Shopify looks set to re-rate as cash flow strengthens, a new buyback supports the s...
Costco just posted strong Q2 FY26 results, fueling a bullish one-year outlook. This article breaks down the data, gro...
Sabre, a travel-technology stalwart, is navigating a recovering travel market and shifting tech spend. This article b...
New neuroscience findings link AI-assisted homework to a sharp decline in student cognitive engagement, prompting pol...
Accredited investors can now access a portfolio of 25,000+ multifamily units via Lightstone's private-market platform...
Trump Mobile says the gold-plated T1 phone will ship this week after nearly year delays, with deposits collected and ...
Florida challenges to the Rooney Rule intensify a national debate over DEI policies in sports. Investors and sponsors...
AI-driven leaders propel gains, yet concentration and margin debt raise the odds of a sharper pullback. Investors wei...
Target reports its strongest quarterly gain in comparable sales in four years, signaling progress in a broad turnarou...
Oceaneering International has staged a striking rally, with a fund-backed bet signaling confidence in continued growt...